Lärkberget (LARK) Investor Update summary

Board composition changes

• Strategic Partner A/S proposes Luca Di Stefano and Jakob Bendtsen as new board members, with Marcus Isaksson re-elected and Lars Thunberg as deputy.

• Luca Di Stefano is nominated as chairman, replacing Jonas Ekblom, Gunilla Lundmark, Peter Nilsson, Per Lundin, and Malin Almgren.

• Luca Di Stefano brings experience in investment, media, IT, and board leadership in several listed and private companies.

• Jakob Bendtsen has over 25 years in auditing, accounting, and consulting, with senior roles in Denmark and the US.

• Lars Thunberg, a CombiGene founder, has 30+ years in finance and business development, with international experience.

Independence and shareholding

• Luca Di Stefano and Jakob Bendtsen are independent of the company and management but not of major shareholders.

• Lars Thunberg is independent of the company, management, and major shareholders.

• Lars Thunberg holds 650,000 shares in CombiGene via a related company.

• Neither Luca Di Stefano nor Jakob Bendtsen hold shares in CombiGene.

Company focus and operations

• CombiGene focuses on gene therapy and advanced treatments for severe diseases.

• Operations include in-licensing, developing assets to proof-of-concept, and out-licensing for commercialization.

• Revenue is generated from milestone payments and royalties.

• Listed on Nasdaq First North Growth Market, with Västra Hamnen Corporate Finance AB as Certified Advisor.